The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components

International Journal of Infectious Diseases

Volumn 12, Issue 3, 2008, Pages 278-288

  Gatchalian, S ^a,b   Palestroque, E ^a   De Vleeschauwer, I ^c   Han, H H ^d   Poolman, J ^c   Schuerman, L ^c   Dobbelaere, K ^c   Boutriau, D ^c  

^a Department of Health   (Philippines)

^b UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d NONE   (Singapore)

Author keywords

Conjugate vaccine; Haemophilus influenzae; Immune memory; Neisseria meningitidis serogroup A; Neisseria meningitidis serogroup C

Indexed keywords

BACTERIAL VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B NEISSERIA MENINGITIDIS TYPE A AND C VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DRUG RESPONSE; DRUG SAFETY; FEVER; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INFLUENZA; IRRITABILITY; MAJOR CLINICAL STUDY; MENINGITIS; NEISSERIA MENINGITIDIS; NEISSERIACEAE INFECTION; PAIN; PERTUSSIS; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; TETANUS; VACCINATION; WHOLE CELL;

ANTIBODIES, BACTERIAL; DIPHTHERIA; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNOLOGIC MEMORY; INFANT; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP A; NEISSERIA MENINGITIDIS, SEROGROUP C; TETANUS; TREATMENT OUTCOME; VACCINES, COMBINED; VACCINES, CONJUGATE; WHOOPING COUGH;

EID: 42249088875     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2007.08.007     Document Type: Article

References (40)

1. World Health Organization. Group A and C meningococcal vaccines. WHO position paper. Wkly Epidemiol Rec 74 (1999) 297-304
2. World Health Organization. Control of epidemic meningococcal disease. WHO practical guidelines. 2nd edition. WHO/EMC/BAC/98.3. Available at: http://www.who.int/csr/resources/publications/meningitis/WHO_EMC_BAC_98_ 3_EN/en/ (accessed September 2007).
3. Traore Y., Njanpop-Lafourcade B.M., Adjogble K.L., Lourd M., Yaro S., Nacro B., et al. The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005. Clin Infect Dis 43 (2006) 817-822
4. Pollard A.J. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 23 12 Suppl (2004) S274-S279
5. Greenwood B. Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 93 (1999) 341-353
6. Campagne G., Schuchat A., Djibo S., Ousseini A., Cisse L., and Chippaux J.P. Epidemiology of bacterial meningitis in Niamey, Niger: 1981-1996. Bull World Health Organ 77 (1999) 499-508
7. World Health Organization. Enhanced surveillance of epidemic meningococcal meningitis in Africa: a three-year experience. Wkly Epidemiol Rec 80 (2005) 313-320
8. Djibo S., Nicolas P., Alonso J.M., Djibo A., Couret D., Riou J.Y., et al. Outbreaks of serogroup X meningococcal meningitis in Niger 1995-2000. Trop Med Int Health 8 (2003) 1118-1123
9. Manchanda V., Gupta S., and Bhalla P. Meningococcal disease: history, epidemiology, pathogenesis, clinical manifestations, diagnosis, antimicrobial susceptibility and prevention. Indian J Med Microbiol 24 (2006) 7-19
10. Hsueh P.R., Teng L.J., Lin T.Y., Chen K.T., Hsu H.M., Twu S.J., et al. Re-emergence of meningococcal disease in Taiwan: circulation of domestic clones of Neisseria meningitidis in the 2001 outbreak. Epidemiol Infect 132 (2004) 637-645
11. World Health Organization. Regional Office for the Western Pacific press release. WHO to help the Philippines investigate disease outbreak. Available at: http://www.wpro.who.int/media_centre/press_releases/news_20050223.htm (accessed October 2006).
12. Miller E., Salisbury D., and Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20 (2002) S58-S67
13. Richmond P., Kaczmarski E., Borrow R., Findlow J., Clark S., McCann R., et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 181 (2000) 761-764
14. Snape M., and Pollard A. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 5 (2005) 21-30
15. World Health Organization. WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 81 (2006) 445-452
16. World Health Organization. Conclusions and recommendations of the Advisory Committee on Poliomyelitis Eradication, Geneva, 11-12 October 2006. Part I. Wkly Epidemiol Rec 81 (2006) 453-460
17. Lopez P., Rubiano L., del Pilar Rubio M., David M.P., and Safary A. Immunogenicity and reactogenicity of DTPw-HBV/Hib vaccine administered to Colombian infants after a birth dose of hepatitis B vaccine. Expert Rev Vaccines 1 (2002) 277-283
18. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 4 (1997) 156-167
19. Borrow R., Andrews N., Goldblatt D., and Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 69 (2001) 1568-1573
20. Gheesling L.L., Carlone G.M., Pais L.B., Holder P.F., Maslanka S.E., Plikaytis B.D., et al. Multicentre comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J Clin Microbiol 32 (1994) 1475-1482
21. Lagos R., Valenzuela M.T., Levine O.S., Losonsky G.A., Erazo A., Wasserman S.S., et al. Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. Lancet 351 (1998) 1472-1476
22. Fernandez J., Balter S., Feris J., Gomez E., Garib Z., Castellanos P.L., et al. Randomized trial of the immunogenicity of fractional dose regimens of PRP-T Haemophilus influenzae type b conjugate vaccine. Am J Trop Med Hyg 62 (2000) 485-490
23. Romero-Steiner S., Fernandez J., Biltoft C., Wohl M.E., Sanchez J., Feris J., et al. Functional antibody activity elicited by fractional doses of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate). Clin Diagn Lab Immunol 8 (2001) 1115-1119
24. Anderson E.L., Frey S., Geldmacher K., Radley D., Lee A., Donnelly J., et al. Safety, tolerability and immunogenicity of low dose Haemophilus influenzae type b conjugated to the outer membrane protein complex of Neisseria meningitidis group B. Pediatr Infect Dis J 21 (2002) 350-352
25. Campbell J.D., Lagos R., Levine M.M., and Losonsky G.A. Standard and alternative regimens of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate vaccine) elicit comparable antibody avidities in infants. Pediatr Infect Dis J 21 (2002) 822-826
26. Tamm E., Veronese A., Contorni M., Meriste S., Nacci P., and Viviani S. Double-blind study comparing the immunogenicity of a licensed DTwPHib-CRM197 conjugate vaccine (Quattvaxem™) with three investigational, liquid formulations using lower doses of Hib-CRM197 conjugate. Vaccine 23 (2005) 1715-1719
27. 197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines. Vaccine 23 (2004) 802-806
28. Richmond P., Borrow R., Miller E., Clark S., Sadler F., Fox A., et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 179 (1999) 1569-1572
29. Borrow R., Goldblatt D., Finn A., Southern J., Ashton L., Andrews N., et al. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom. Infect Immun 71 (2003) 5549-5555
30. Rennels M., King Jr. J., Ryall R., Papa T., and Froeschle J. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 23 (2004) 429-435
31. Twumasi Jr. P.A., Kumah S., Leach A., O'Dempsey T.J., Ceesay S.J., Todd J., et al. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 171 (1995) 632-638
32. Borrow R., Fox A.J., Richmond P.C., Clark S., Sadler F., Findlow J., et al. Induction of immunological memory in UK infants by a meningococcal A/C conjugate vaccine. Epidemiol Infect 124 (2000) 427-432
33. Leach A., Twumasi P.A., Kumah S., Banya W.S., Jaffar S., Forrest B.D., et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis 175 (1997) 200-204
34. Pollard A.J., and Frasch C. Development of natural immunity to Neisseria meningitidis. Vaccine 19 (2001) 1327-1346
35. De Vleeschauwer I, Weynants V, Durant N, Feron C, Boutriau D, Poolman J. MenA natural immunity and SBA tests with A:L10 and A:L11 target strains. 15th International Pathogenic Neisseria Conference, Cairns, Queensland, Australia, 10-15 September 2006; abstract P8.1.18.
36. Ramsay M.E., McVernon J., Andrews N.J., Heath P.T., and Slack M.P. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 188 (2003) 481-485
37. Trotter C.L., Andrews N.J., Kaczmarski E.B., Miller E., and Ramsay M.E. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364 (2004) 365-367
38. Ismail A.A., Harris S.L., and Granoff D.M. Serum group A anticapsular antibodies in a Sudanese population immunized with meningococcal polysaccharide vaccine during a group A epidemic. Pedriatr Infect Dis J 23 (2004) 7488-7555
39. Hassan-King M.K., Wall R.A., and Greenwood B.M. Meningococcal carriage, meningococcal disease and vaccination. J Infect 16 (1988) 55-59
40. Chippaux J.P., Dallio A., Marra A., and Étard J.F. Impact of previous immunization on the incidence of meningococcal disease during an outbreak in a Sahelian area of Senegal. Vaccine 25 (2007) 1712-1718